Optimer Teams With AztraZeneca To Bring Dificid To South America
This article was originally published in PharmAsia News
Executive Summary
Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.
You may also be interested in...
Optimer's Deal With Cubist Gives Dificid Experienced Hospital Sales Force Support
Optimer expects the co-promotion to accelerate formulary adoption and uptake of the antibiotic at the 1,100 hospitals where 70% of hospital-related Clostridium dificile infections occur.
Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.
ArsenalBio Adds Genentech As A Partner While Embarking On Internal CAR-T Program
The start-up will secure $70m from Genentech, after closing a series B financing, while it moves its first CAR-T program into the clinic for ovarian cancer later this year.